Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice.

Journal of immunology (Baltimore, Md. : 1950) - 15 Dec 2012

Baccala Roberto, Gonzalez-Quintial Rosana, Schreiber Robert D, Lawson Brian R, Kono Dwight H, Theofilopoulos Argyrios N

Abstract excerpt

The demonstration in humans and mice that nucleic acid-sensing TLRs and type I IFNs are essential disease mediators is a milestone in delineating the mechanisms of lupus pathogenesis. In this study, we show that Ifnb gene deletion does not modify disease progression in NZB mice, thereby strongly implicating IFN-α subtypes as the principal pathogenic effectors. We further document that long-term treatment of male...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Antinuclear
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Autoantibodies

Share to Lupus Nephritis

Share to Mice, Inbred MRL lpr

Share to Mice, Inbred NZB

Share to Proteinuria

Share to Receptor, Interferon alpha-beta

Source

Open in PubMed Open full text

Identifiers

PMID: 23175700
DOI: 10.4049/jimmunol.1201477
PMCID: PMC3530925

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice.PMID 23175700Read ↗

Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB MiceSemantic proximity Read ↗

Type I interferon signaling is involved in the spontaneous development of lupus-like disease in B6.Nba2 and (B6.Nba2 x NZW)F(1) mice.Semantic proximity Read ↗

Assessing the Molecular Validity of Spontaneous Lupus Mouse Models and Its Implication for Human StudiesSemantic proximity Read ↗

Interferon-alpha treatment of female (NZW x BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation.Semantic proximity Read ↗

Exacerbated Autoimmunity in the Absence of TLR9 in MRL. <i>Faslpr</i> Mice Depends on <i>Ifnar1</i>Semantic proximity Read ↗

FcgammaRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease.Semantic proximity Read ↗

Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc.Semantic proximity Read ↗

Spontaneous CD4+ T Cell Activation and Differentiation in Lupus-Prone B6.Nba2 Mice Is IFNAR-Independent.Semantic proximity Read ↗

Animal Models of Interferon Signature Positive LupusSemantic proximity Read ↗

IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice.Semantic proximity Read ↗

Targeting of type I interferon in systemic autoimmune diseases.Semantic proximity Read ↗

Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.